<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Summary of recommendations for transplantation for hepatocellular carcinoma from an International Consensus Conference</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Summary of recommendations for transplantation for hepatocellular carcinoma from an International Consensus Conference</h1>
<div class="graphic"><div class="figure"><div class="ttl">Summary of recommendations for transplantation for hepatocellular carcinoma from an International Consensus Conference</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Level of evidence</td> <td class="subtitle1">Strength of recommendation</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Assessment of candidates with HCC for liver transplantation</td> </tr> <tr> <td class="indent1"><strong>1.</strong> When considering treatment options for patients with HCC, the BCLC staging system is the preferred staging system to assess the prognosis of patients with HCC.</td> <td>2b (P)</td> <td>Strong</td> </tr> <tr> <td class="indent1"><strong>2.</strong> The TNM system (7th edition), including pathological examination of the explanted liver, should be used for determining prognosis after transplantation with the addition of assessment of microvascular invasion.</td> <td>2b (P)</td> <td>Strong</td> </tr> <tr> <td class="indent1"><strong>3.</strong> Either dynamic CT or dynamic MRI with the presence of arterial enhancement followed by washout on portal venous or delayed imaging is the best non-invasive test to make a diagnosis in cirrhotic patients suspected of having HCC and for preoperative staging.</td> <td>1b (D)</td> <td>Strong</td> </tr> <tr> <td class="indent1"><strong>4.</strong> Extrahepatic staging should include CT of the chest and CT or MRI of the abdomen and pelvis.</td> <td>3b (D)</td> <td>Strong</td> </tr> <tr> <td class="indent1"><strong>5.</strong> Tumor biopsy is not required in cirrhotic patients considered for liver transplantation who have high-quality dynamic CT or MRI findings typical for HCC and a lesion larger than 1 cm according to current AASLD guidelines.</td> <td>1b (D)</td> <td>Weak</td> </tr> <tr> <td class="indent1"><strong>6.</strong> For patients with lesions smaller or equal to 10 mm, non-invasive imaging does not allow an accurate diagnosis and should not be used to make a decision for or against transplantation.</td> <td>1b (D)</td> <td>Strong</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Criteria for listing candidates with HCC in cirrhotic livers for DDLT</td> </tr> <tr> <td class="indent1"><strong>7.</strong> Liver transplantation should be reserved for HCC patients who have a predicted five-year survival comparable to non-HCC patients.</td> <td>NA</td> <td>Weak</td> </tr> <tr> <td class="indent1"><strong>8.</strong> Preoperative assessment of the size of the largest tumor or total diameter of tumors should be the main consideration in selecting patients with HCC for liver transplantation.</td> <td>2a (P)</td> <td>Strong</td> </tr> <tr> <td class="indent1"><strong>9.</strong> The Milan criteria are currently the benchmark for the selection of HCC patients for liver transplantation and the basis for comparison with other suggested criteria.</td> <td>2a (P)</td> <td>Strong</td> </tr> <tr> <td class="indent1"><strong>10.</strong> A modest expansion of the number of potential candidates may be considered on the basis of several studies showing comparable survival for patients outside the Milan criteria.</td> <td>3b (P)</td> <td>Weak</td> </tr> <tr> <td class="indent1"><strong>11.</strong> Patients with worse prognosis may be considered for liver transplantation outside the Milan criteria if the dynamics of the waiting list allow it without undue prejudice to other recipients with a better prognosis.</td> <td>NA</td> <td>Weak</td> </tr> <tr> <td class="indent1"><strong>12.</strong> α-fetoprotein concentrations add prognostic information in HCC patients and may be used for making decisions regarding transplantation in combination with imaging criteria.</td> <td>2b (P)</td> <td>Weak</td> </tr> <tr> <td class="indent1"><strong>13.</strong> Biomarkers other than α-fetoprotein cannot yet be used for clinical decision making regarding liver transplantation for HCC.</td> <td>2b (P)</td> <td>Strong</td> </tr> <tr> <td class="indent1"><strong>14.</strong> Indication for liver transplantation in HCC should not rely on microvascular invasion because it cannot be reliably detected prior to transplantation.</td> <td>2b (P)</td> <td>Strong</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Criteria for HCC candidates with non-cirrhotic livers</td> </tr> <tr> <td class="indent1"><strong>15.</strong> The Milan criteria and its modifications are not applicable to patients with HCC developing in a non-cirrhotic liver. Such patients with non-resectable HCC and absence of macrovascular invasion and extrahepatic spread may be considered as appropriate candidates for liver transplantation.</td> <td>4 (P)</td> <td>Weak</td> </tr> <tr> <td class="indent1"><strong>16.</strong> Patients with HCC in non-cirrhotic liver who were treated by resection, and have intrahepatic recurrence of HCC and no evidence of lymph node or macrovascular invasion, may be considered for salvage transplantation.</td> <td>4 (P)</td> <td>Weak</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Role of downstaging</td> </tr> <tr> <td class="indent1"><strong>17.</strong> Transplantation may be considered after successful downstaging.</td> <td>5 (P)</td> <td>Weak</td> </tr> <tr> <td class="indent1"><strong>18.</strong> Liver transplantation after successful downstaging should achieve a five-year survival comparable to that of HCC patients who meet the criteria for liver transplantation without requiring downstaging.</td> <td>5 (P)</td> <td>Strong</td> </tr> <tr> <td class="indent1"><strong>19.</strong> Criteria for successful downstaging should include tumor size and number of viable tumors.</td> <td>4 (P)</td> <td>Strong</td> </tr> <tr> <td class="indent1"><strong>20.</strong> α-fetoprotein concentrations before and after downstaging may add additional information.</td> <td>4 (P)</td> <td>Weak</td> </tr> <tr> <td class="indent1"><strong>21.</strong> Based on existing evidence, no recommendation can be made for preferring a specific locoregional therapy for downstaging over others.</td> <td>NA</td> <td>None</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Managing patients on the waiting list</td> </tr> <tr> <td class="indent1"><strong>22.</strong> Periodic waiting-list monitoring should be performed by imaging (dynamic CT, dynamic MRI, or contrast-enhanced ultrasonography) and α-fetoprotein measurements.</td> <td>5 (P)</td> <td>Strong</td> </tr> <tr> <td class="indent1"><strong>23.</strong> Based on current absence of evidence, no recommendation can be made on bridging therapy in patients with UNOS T1 (≤2 cm) HCC.</td> <td>NA</td> <td>None</td> </tr> <tr> <td class="indent1"><strong>24.</strong> In patients with UNOS T2 (one nodule 2 to 5 cm or three or more nodules each ≤3 cm) HCC (Milan criteria) and a likely waiting time longer than six months, locoregional therapy may be appropriate.</td> <td>4 (P)</td> <td>Weak</td> </tr> <tr> <td class="indent1"><strong>25.</strong> No recommendation can be made for preferring any type of locoregional therapy to others.</td> <td>NA</td> <td>None</td> </tr> <tr> <td class="indent1"><strong>26.</strong> Patients found to have progressed beyond criteria acceptable for listing for liver transplantation should be placed on hold and considered for downstaging.</td> <td>5 (P)</td> <td>Strong</td> </tr> <tr> <td class="indent1"><strong>27.</strong> Patients with progressive disease in whom locoregional intervention is not considered appropriate, or is ineffective, should be removed from the waiting list.</td> <td>5 (P)</td> <td>Strong</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Role of LDLT</td> </tr> <tr> <td class="indent1"><strong>28.</strong> LDLT is acceptable for HCC patients who have an expected five-year survival similar to comparably staged patients receiving a deceased donor liver. In LDLT, careful attention should be given to psychosocial considerations regarding both donor and recipient.</td> <td>NA</td> <td>Weak</td> </tr> <tr> <td class="indent1"><strong>29.</strong> LDLT must be restricted to centers of excellence in liver surgery and liver transplantation to minimize donor risk and maximize recipient outcome.</td> <td>NA</td> <td>Strong</td> </tr> <tr> <td class="indent1"><strong>30.</strong> In patients following LDLT for HCC within the accepted regional criteria for DDLT, retransplantation for graft failure is justified.</td> <td>5 (P)</td> <td>Weak</td> </tr> <tr> <td class="indent1"><strong>31.</strong> In patients following LDLT for HCC outside the accepted regional criteria for DDLT, retransplantation for graft failure using a deceased donor organ is not recommended.</td> <td>5 (P)</td> <td>Strong</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Posttransplant management</td> </tr> <tr> <td class="indent1"><strong>32.</strong> Posttransplant monitoring may include 6 to 12 monthly contrast-enhanced CT or MRI imaging and α-fetoprotein measurements.</td> <td>5 (P)</td> <td>Weak</td> </tr> <tr> <td class="indent1"><strong>33.</strong> There is currently insufficient evidence from clinical trials to base a recommendation for choosing the type or dose of immunosuppression therapy to influence the incidence of HCC recurrence or its prognosis.</td> <td>NA</td> <td>None</td> </tr> <tr> <td class="indent1"><strong>34.</strong> Based on current evidence, no recommendation can be made on the use of mTOR inhibitors solely to reduce the risk of HCC recurrence outside clinical trials.</td> <td>NA</td> <td>None</td> </tr> <tr> <td class="indent1"><strong>35.</strong> The current evidence does not justify the routine use of adjuvant antitumor therapy after liver transplantation for HCC outside of a controlled clinical trial.</td> <td>NA</td> <td>Weak</td> </tr> <tr> <td class="indent1"><strong>36.</strong> HCC recurrence after liver transplantation may be treated by surgery for resectable lesions or by locoregional therapy or systemic therapy (including sorafenib) for unresectable lesions.</td> <td>4 (p)</td> <td>Weak</td> </tr> <tr> <td class="indent1"><strong>37.</strong> Liver retransplantation is not appropriate treatment for recurrent HCC.</td> <td>NA</td> <td>Strong</td> </tr> </tbody></table></div><div class="graphic_lgnd">Level of evidence for each recommendation refers to the Oxford classification.</div><div class="graphic_footnotes">HCC: hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer; TNM: tumor, node, metastasis; P: prognosis; D: diagnosis; AASLD: American Association for the Study of Liver Diseases; NA: not applicable; OLT: orthotopic liver transplantation; UNOS: United Network for Organ Sharing; LDLT: living donor liver transplantation; DDLT: deceased donor liver transplantation; mTOR: mammalian target of rapamycin.</div><div class="graphic_reference">Reproduced from: Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13:e11. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id="graphicVersion">Graphic 83727 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
